| Literature DB >> 30510574 |
Kwangu M Kanama1, Adegbenro P Daso1, Lizzy Mpenyana-Monyatsi1, Marthie A A Coetzee1.
Abstract
The presence of 17 pharmaceutical and personal care products (PPCPs) belonging to various therapeutic categories was investigated in two hospital wastewater treatment plants (WWTPs) in North West Province, South Africa. The compounds were extracted from wastewater samples by solid-phase extraction and analysed by liquid chromatography-tandem mass spectrometry. The results showed that ofloxacin, chloramphenicol, and bezafibrate were generally below the limit of quantification (LOQ) in the analysed samples. Acetaminophen and ibuprofen were the dominant pharmaceuticals in the influent streams with corresponding concentrations ranging from 21 to 119 μg/L and 0.3 to 63 μg/L, respectively. Both WWTPs were shown to have the capability to remove some of the target PPCPs, including acetaminophen (76-98%), tetracycline (15-93%), ibuprofen (44-99%), and triclocarban (13-98%). The monitoring of the target PPCPs in both influent and effluent samples of the investigated WWTPs revealed that the discharge of inadequately treated effluents could be contributing to the possible increase in the concentrations of these contaminants in the receiving environmental compartments. Further studies must be focused on the broader characterisation of these matrices in order to assess the potential ecological impacts of this waste disposal practice.Entities:
Year: 2018 PMID: 30510574 PMCID: PMC6232802 DOI: 10.1155/2018/3751930
Source DB: PubMed Journal: J Toxicol ISSN: 1687-8191
Concentrations of different types of pharmaceuticals in HWW from the reviewed studies.
|
|
| |
|---|---|---|
|
|
| |
|
| ||
|
| ||
| Ciprofloxacin | 0.85-2 | Brown et al., 2006 [ |
| 2.0-83 | Kümmerer et al., 2001 [ | |
| 3.6-101 | Lindberg et al., 2004 [ | |
|
| ||
| Ofloxacin | 2.905 | Chang et al., 2010 [ |
| 6.67 | Gros et al., 2013 [ | |
| 2.20 | Passerat et al | |
|
| ||
| Nalidixic acid | 0.186 | Lin et al., 2008 [ |
|
| ||
| <0.002-<0.005 | Gros et al.,2013 [ | |
| Tetracycline | <0.015-4.178 | Thomas et al |
| <0.002-0.455 | Lin & Tsai, 2009 [ | |
| <0.007-0.033 | Verlicchi et al., 2012a [ | |
|
| ||
| Chloramphenicol | <0.004-0.036 | Verlicchi et al., 2012a [ |
| 0.001 | Lin et al | |
| <0.5 | Ohlsen et al., 2003 [ | |
|
| ||
|
| ||
| Estrone | 0.007-0.04 | Thomas et al |
| <0.01 | Lin et al., 2008 [ | |
| 0.025-0.415 | Lin & Tsai, 2009 [ | |
|
| ||
| 17 | <0.003-0.072 | Thomas et al.,2007 [ |
| <0.025-0.23 | Thomas et al., 2007 [ | |
| <0.01 | Lin et al., 2008 [ | |
|
| ||
| Estriol | 0.18-0.785 | Thomas et al.,2007 [ |
| 4.651 | Lin et al., 2008 [ | |
|
| ||
| 17 | <0.003 | Thomas et al., 2007 [ |
| <0.025-0.432 | Lin & Tsai, 2009 [ | |
| <0.0004 | Perrodin et al., 2013 [ | |
|
| ||
|
| ||
| Atenolol | 0.045-0.0053 | Langford & Thomas, 2009 [ |
| 0.1-122 | Gómez et al., 2006 [ | |
| 2.2-6.6 | Verlicchi et al | |
|
| ||
|
| ||
| Triclosan | <0.044 | Kosma et al., 2010 [ |
|
| ||
|
| ||
| Bezafibrate | <0.001-2.9 | Verlicchi et al., 2012 [ |
|
| ||
|
| ||
| Diclofenac | 0.06-1.9 | Gómez et al., 2006 [ |
| 0.17-0.53 | Verlicchi et al., 2012 [ | |
| 0.028-6.88 | Sim et al., 2011 [ | |
|
| ||
| Acetaminophen | 0.5-29 | Gómez et al., 2006 [ |
| 1.4-5.9 | Verlicchi et al., 2012b [ | |
| 0.271-63.1 | Sim et al., 2011 [ | |
|
| ||
| Ibuprofen | 7-8.93 | Kosma et al., 2010 [ |
| 1.5-151 | Gómez et al., 2006 [ | |
| 0.069-8.957 | Thomas et al., 2007 [ | |
|
| ||
| Ketoprofen | 0.2-0.35 | Langford |
| 1.1-9.8 | Verlicchi et al., 2012 [ | |
| <0.01-0.23 | Lin & Tsai, 2009 [ | |
Selected pharmaceuticals and their physicochemical properties.
| Pharmaceutical class | Compound | MW | Log KOW |
|---|---|---|---|
| Antibiotics | Ciprofloxacin | 331.35 | 0.28 |
| Ofloxacin | 361.4 | -0.39 | |
| Norfloxacin | 319.34 | -0.13 | |
| Tetracycline | 444.44 | -1.3 | |
| Beta-blockers | Atenolol | 266.3 | 0.16 |
| Disinfectants | Triclosan | 289.54 | 4.76 |
| Triclocarban | 315.58 | 4.9 | |
| Analgesics/anti-inflammatory drugs | Diclofenac | 294 | 4.51 |
| Acetaminophen | 151.2 | 0.46 | |
| Ibuprofen | 206.3 | 3.97 | |
| Ketoprofen | 254.3 | 3.12 | |
| Lipid modifying agents | Bezafibrate | 361.8 | 4.25 |
| Steroid hormones | Estrone | 270.4 | 3.13 |
| Estriol | 288.4 | 2.45 | |
| 17 | 272.4 | 4.01 | |
| 17 | 296.4 | 4.2 |
Physical and chemical information was obtained from Ratola et al., 2012 [45]; Shaver, 2011 [46].
Figure 1Map showing the North West Province and the sampling points depicted by the black dot.
Mass spectrometry parameters for pharmaceutical and hormone analysis (quantitative ion marked in bold; confirmation ion).
|
|
|
|
|
|
|---|---|---|---|---|
|
| ||||
| Ketoprofen (KET) | 253.3 |
| 15 | 8 |
| Ibuprofen (IBU) | 205.4 |
| 17 | 9 |
| Bezafibrate (BEZ) | 360.2 |
| 13 | 16 |
| Triclosan (TCS) | 286.8 |
| 22 | 11 |
| Triclocarban (TCC) | 313.1 |
| 12 | 13 |
| Chloramphenicol | 321.1 |
| 16 | 19 |
| Estrone (E1) | 269.2 |
| 14 | 46 |
| 17 | 271.2 |
| 14 | 47 |
| Estriol (E3) | 287.2 |
| 15 | 43 |
| 17 | 295.3 |
| 11 | 47 |
|
| ||||
| Tetracycline (TCN) | 444.9 |
| -13 | -21 |
| Nalidixic acid (NAL) | 232.9 |
| -18 | -16 |
| Atenolol (ATE) | 267 |
| -14 | -29 |
| Acetaminophen (ACE) | 151.9 |
| -11 | -24 |
| Ofloxacin (OFL) | 362 |
| -14 | -22 |
| Norfloxacin (NOR) | 320 |
| -16 | -22 |
| Ciprofloxacin (CIP) | 332 |
| -13 | -23 |
| Diclofenac sodium salt (DIC) | 318 |
| -12 | -15 |
Method validation parameters.
|
|
| % |
|
|
|---|---|---|---|---|
|
| 0.9995 | 1 | 0.03 | 0.102 |
|
| 0.9997 | 26.28 | 0.06 | 0.18 |
|
| 0.9997 | 18.07 | 0.05 | 0.15 |
|
| 0.9991 | 8.49 | 0.04 | 0.12 |
|
| 0.9994 | 24.72 | 1.66 | 5.02 |
|
| 0.9979 | 7.34 | 0.4 | 1.22 |
|
| 0.9999 | 101.92 | 0.17 | 0.51 |
|
| 0.9997 | 101.92 | 0.07 | 0.22 |
|
| 0.9992 | 32.08 | 0.05 | 1.23 |
|
| 0.9999 | 28.6 | 0.13 | 0.38 |
|
| 0.9999 | 12.51 | 0.19 | 0.59 |
|
| 0.9991 | 67.5 | 0.07 | 0.23 |
|
| 0.9996 | 25.97 | 0.79 | 2.41 |
|
| 0.9988 | 10.22 | 1.3 | 3.93 |
|
| 0.9993 | 81.07 | 0.38 | 1.71 |
|
| 0.9992 | 23.66 | 0.6 | 1.82 |
|
| 0.9995 | 4.19 | 0.11 | 0.33 |
LOD: limit of detection; LOQ: limit of quantification; RSD: relative standard deviation.
Percentage recovery of pharmaceuticals.
|
|
| |
|---|---|---|
|
|
| |
| E1 | 146 | 101 |
| E3 | 88 | 92 |
| E2 | 70 | 113 |
| EE2 | 75 | 90 |
Overall concentrations of pharmaceuticals in influents and effluents (μg/L) in WWTP-A.
| WWTP-A | Influent | Effluent | ||
|---|---|---|---|---|
| Mean conc. | Min-Max conc. | Mean conc. | Min-Max conc. | |
|
| ||||
| CIP | 0.99 ± 0.80 | 0.12-2.00 | 0.51 ± 0.57 | 0.08-1.40 |
| OFL | ND | ND | ND | ND |
| NOR | 0.42 ± 0.62 | 0.10-1.53 | 0.12 ± 0.13 | 0.03-0.35 |
| CAL | ND | ND | ND | ND |
| TCN | 11.04 ± 19.22 | 1.09-45.38 | 0.95 ± 0.38 | 0.52-1.43 |
|
| ||||
| ATE | 4.41 ± 2.76 | 1.08-8.34 | 1.19 ± 1.27 | 0.33-3.22 |
|
| ||||
| TCS | ND | ND | ND | ND |
| TCC | 0.76 ± 0.67 | 0.23-1.75 | 0.11 ± 0.19 | 0.01-0.46 |
|
| ||||
| DIC | 2.38 ± 4.46 | 0.12-10.34 | 0.3 ± 0.27 | 0.07-0.75 |
| ACE | 49.79 ± 40.43 | 21.27-119.50 | 6.1 ± 7.50 | <LOQ-11.39 |
| IBU | 16.44 ± 23.23 | 0.33-53.40 | 5.25 ± 7.35 | <LOQ-13.66 |
| KET | 0.39 ± 0.38 | <LOQ-0.65 | 0.14 ± 0.08 | <LOQ-0.24 |
|
| ||||
| BF | ND | ND | ND | ND |
|
| ||||
| E1 | 0.031 ± 0.02 | 0.013-0.053 | 0.023 ± 0.014 | 0.007-0.041 |
| E3 | 0.463 ± 0.57 | 0.134-1.480 | 0.233 ± 0.157 | 0.111-0.539 |
| | 0.022 ± 0.02 | 0.008-0.035 | 0.014 ± 0.004 | 0.008-0.0191 |
| EE2 | 5.601 ± 2.66 | 2.654-9.833 | 1.344 ± 1.827 | 0.448-4.608 |
ND: not detected.
Overall concentrations of pharmaceuticals in influents and effluents (μg/L) in WWTP-B.
| WWTP-B | Influent | Effluent | ||
|---|---|---|---|---|
| Mean conc. | Min-Max conc. | Mean conc. | Min-Max conc. | |
|
| ||||
| CIP | 2.2 ± 3.89 | 0.12-9.11 | 0.35 ± 0.52 | 0.06-1.28 |
| OFL | ND | ND | ND | ND |
| NOR | 0.26 ± 0.31 | 0.07-0.82 | 0.15 ± 0.19 | 0.02-0.44 |
| CAL | ND | ND | ND | ND |
| TCN | 19.11 ± 31.73 | 3.80-75.81 | 1.49 ± 1.12 | 0.48-3.22 |
|
| ||||
| ATE | 1.19 ± 0.89 | 0.41-2.54 | 0.71 ± 0.82 | 0.15-2.15 |
|
| ||||
| TCS | 0.11 ± 0.19 | 0.00-0.40 | 0.09 ± 0.12 | 0.00-0.27 |
| TCC | 0.61 ± 0.38 | 0.06-0.97 | 0.04 ± 0.03 | 0.00-0.06 |
|
| ||||
| DIC | 0.99 ± 1.59 | 0.15-3.82 | 0.47 ± 0.63 | 0.10-1.58 |
| ACE | 24.07 ± 22.47 | 11.06-57.65 | 1.24 ± 1.19 | <LOQ-2.09 |
| IBU | 14.39 ± 27.40 | 1.09-63.37 | 0.51 ± 0.61 | 0.02-1.46 |
| KET | 0.53 ±0.25 | <LOQ-0.70 | 0.23 ± 0.32 | <LOQ-0.61 |
|
| ||||
| BF | ND | ND | ND | ND |
|
| ||||
| E1 | 0.018 ± 0.014 | 0.004-0.040 | 0.004 ± 0.002 | 0-6 |
| E3 | 0.257 ± 0.199 | 0.027-0.512 | 0.043 ± 0.024 | 0.01-0.065 |
| Β-E2 | 0.0178 ± 0.020 | 0.001-0.047 | <LOQ | |
| EE2 | 0.923 ± 0.067 | 0.881-1.041 | 0.681 ± 0.130 | 0.524-0.884 |
ND: not detected.
Figure 2Average removal of pharmaceuticals in both WWTPs.